Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
BLISSGVS

Bliss GVS Pharma Share Price

 
Stock touched all time high

 

Bliss GVS Pharma live price: ₹297.8.

Bliss GVS Pharma Performance

  • Today's Low
  • ₹279
  • Today's High
  • ₹292
  • 52 Week Low
  • ₹118
  • 52 Week High
  • ₹301
  • Open Price₹285
  • Previous Close₹0
  • Volume1,139,806
  • 50 DMA₹253.55
  • 100 DMA₹227.94
  • 200 DMA₹200.00

Bliss GVS Pharma Chart

Investment Returns

  • Over 1 Month + 15.07%
  • Over 3 Month + 33.39%
  • Over 6 Month + 86.37%
  • Over 1 Year + 145.02%

Smart Investing Starts Here Start SIP with Bliss GVS Pharma for Steady Growth!

Invest Now

Bliss GVS Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 24.4
  • PEG Ratio
  • 0.5
  • Market Cap Cr
  • 3,150
  • P/B Ratio
  • 2.7
  • Average True Range
  • 13.2
  • EPS
  • 12.36
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 10.7
  • RSI
  • 66.47
  • MFI
  • 80.79

Latest Stock News Updates

Q4FY26 & FY26 Result Announced for Bliss GVS Pharma Ltd.

Pharmaceuticals company Bliss GVS Pharma announced Q4FY26 & FY26 results Revenue from operations stood at Rs 25,690 lakhs in Q4FY26 compared to Rs 19,798 lakhs in Q4FY25 PBT stood at Rs 4,404 lakhs in Q4FY26 compared to Rs 2,344 lakhs in Q4FY25 Net Profit stood at Rs 3,699 lakhs in Q4FY26 compared to Rs 1,665 lakhs in Q4FY25 Revenue from operations stood at Rs 92,711 lakhs in FY26 compared to Rs 80,972 lakhs in FY25 PBT stood at Rs 18,958 lakhs in FY26 compared to Rs 12,563 lakhs in FY25 Net Profit stood at Rs 13,427 lakhs in FY26 compared to Rs 9,025 lakhs in FY25 Result PDF

Q2FY22 Quarterly Result Announced for Bliss GVS Pharma Ltd.

Key Highlights Revenue from Operation Rs 30,745.88 Lakhs EBITDA Rs 5,869.56 Lakhs 19% Revenue from Operation Rs 23,284.38 Lakhs EBITDA Rs 4,498.07 Lakhs 19% Other Income Rs 1388.20 Lakhs Other Income Rs 1013.00 Lakhs PBT Rs 6381.44 Lakhs 20% PBT Rs 4,667.44 Lakh 19% PAT Rs 4,638.54 Lakhs 14% PAT Rs 3,588.33 Lakhs 15% Result PDF

Promoters sell shares in Bliss GVS, Polus Global Fund picks up 8%

Multiple promoter and promoter group entities in Bliss GVS Pharma have sold shares over the past week on the market via insider trades. This included a share sale by Promoter Director Narasimha Kamath, who sold 3.55% of total shares on the market for an average price of Rs. 152.8. The company is currently trading at Rs. 160 share price on the stock market. Also selling off Bliss shares were three other promoter group or promoter-directors. In all, 10.6% of Bliss GVS shares were disposed of in the market. FII Polus Global Fund has acquired 8.04% of the company via an SAST transaction.

Bliss GVS Pharma Financials

Bliss GVS Pharma Technicals

EMA & SMA

Current Price
₹297.80
+ 2.6 (0.88%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹275.43
  • 50 Day
  • ₹253.55
  • 100 Day
  • ₹227.94
  • 200 Day
  • ₹200.00

Resistance and Support

294.83 Pivot Speed
  • R3 315.42
  • R2 308.43
  • R1 301.82
  • S1 288.22
  • S2 281.23
  • S3 274.62

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Bliss GVS Pharma manufactures and exports pharmaceutical products, specializing in suppositories, pessaries, and oral medications. With a global presence in over 60 countries, it serves therapeutic segments like anti-malarial, antibiotics, and dermatology through its state-of-the-art facilities.

Bliss Gvs Pharma has an operating revenue of Rs. 927.11 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 20% is great, ROE of 10% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 17% and 54% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 21% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 57 which is a POOR score indicating inconsistency in earnings, a RS Rating of 95 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 51 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Bliss GVS Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-12 Audited Results & Final Dividend
2026-02-10 Quarterly Results & Interim Dividend
2025-11-06 Quarterly Results
2025-07-29 Quarterly Results
2025-05-12 Audited Results & Final Dividend
Date Purpose Remarks
2026-02-18 INTERIM Rs.0.50 per share(50%)Interim Dividend
2025-07-24 FINAL Rs.0.50 per share(50%)Final Dividend
View Bliss GVS Pharma Dividend History Arrow

Bliss GVS Pharma Shareholding Pattern

35.36%
0%
4.33%
10.45%
32.6%
17.26%

Bliss GVS Pharma FAQs

Bliss GVS Pharma share price is ₹297 As on 22 May, 2026 | 12:51

The Market Cap of Bliss GVS Pharma is ₹3150.4 Cr As on 22 May, 2026 | 12:51

The P/E ratio of Bliss GVS Pharma is 24.4 As on 22 May, 2026 | 12:51

The PB ratio of Bliss GVS Pharma is 2.7 As on 22 May, 2026 | 12:51

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23